Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma Business
-
By Donald Zuhn — While the recession has certainly had an effect on biotech/pharma patent filings, the recession appears to have had little impact on lobbying expenditures in the biotech/pharma industry. With the reporting period for first quarter lobbying now passed, many biotech/pharma companies and organizations not only kept pace with, but handily surpassed,…
-
By Kevin E. Noonan — Last week, Biogen Idec sponsored a "Super Session" at the BIO 2009 International Conference entitled "Weathering the Perfect Storm of Financial Distress and Political Pressure." The session was moderated by Stephen Sands, Lazard Freres & Co., for a panel consisting of Broderick D. Johnson, Bryan Cave; Scott Gottlieb M.D.,…
-
By Kevin E. Noonan — What a difference a year makes. Steven Burrill (at right), President and CEO of Burrill & Co., unveiled his company's "State of the Biotechnology Industry" report on Tuesday at BIO 2009 in Atlanta. Mr. Burrill described what he termed "a sea change" that has occurred over the past several…
-
By Sherri Oslick — In a Super Session held Tuesday morning at the BIO 2009 conference, Ernst & Young hosted "Beyond Borders — Ernst & Young's Global Biotechnology Report 2009," a presentation that summarized the financial performance of the biotechnology industry in 2008 and addressed related issues and trends. The session consisted of brief…
-
By Donald Zuhn — Late last week, PricewaterhouseCoopers and the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, announced the release of their quarterly MoneyTree Report (based on data from Thomson Reuters), which showed that venture capitalists had invested $3.0 billion in 549 deals in the first quarter…
-
By Donald Zuhn — The new year has witnessed yet another blockbuster biotech/pharma deal. On the heels of Pfizer's $68 billion acquisition of Wyeth (see "Pfizer Expected to Announce Wyeth Acquisition on Monday") in January, Merck & Co., Inc. and Schering-Plough Corp. announced today that their Boards of Directors had unanimously approved a definitive…
-
By Kevin E. Noonan — The Biotechnology Industry Organization (BIO) held one of its periodic meetings with the press today for a wide-ranging discussion of its policy goals and agendas for the new Congress and administration. A panel of BIO officials, headed by President and CEO James Greenwood, answered questions from more than a…
-
By Kevin E. Noonan — In an ironic twist, the worst economic downturn in over seventy years seems to have coincided with an economic first: according to G. Steven Burrill (at right), CEO of Burrill & Co., in 2008, the biotechnology industry became profitable for the first time in its forty-year history (see FierceBiotech…
-
By Jason Derry* and Donald Zuhn —GPC Biotech and Agennix to Merge GPC Biotech AG and Agennix Inc. have announced a plan to merge. Both companies are focused on discovering and developing treatments for cancer. A new company will be formed with the help of cash from the investment company dievini Hopp Biotech. GPC…
-
By Donald Zuhn — In December, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, issued its forecast for venture investment in the coming year, predicting that most sectors would see a continued slowdown in investment in 2009 (see "NVCA Predicts Another Slow Year for Venture-backed Businesses in…
Patent Docs 